Kwality Pharmaceuticals Q1FY23 profit at Rs. 10.52 Cr

The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.

Fish & Richardson secures win for Exela Pharma Sciences in ELCYS patent infringement litigation

ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions

QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency

QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms

Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen

All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied

Parmax Pharma posts Q1 FY 23 loss at Rs. 1.31 Cr

The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022

Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr

The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr

The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.

Vascular experts establish appropriate use of IVUS in peripheral interventions

Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions

AstraZeneca completes acquisition of TeneoTwo

AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean

GL Chemtech partners with Edgewater Capital to accelerate growth

Investment in response to increased demand for North American-based chemistry services

Hikal shows 17% degrowth in Q1 FY23

Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr

The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.

ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs

Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr

The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.

Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr

The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.

IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr

The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.

Max Healthcare Institute Q1 FY23 consolidated PAT soars at Rs. 172.83 Cr

The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.